Camelot Portfolios LLC Acquires New Shares in Becton, Dickinson and Company $BDX

Key Points

• Camelot Portfolios LLC acquired a new stake in Becton, Dickinson and Company (NYSE: BDX) by purchasing 3,754 shares valued at approximately $647,000 in the second quarter.
• Insider transactions revealed that EVP Michael David Garrison sold 1,185 shares at an average price of $180.29, representing a 19.52% decrease in his position, while Director Claire Fraser also sold 917 shares at $187.50.
• Analysts have mixed views on BDX, with Barclays lowering its price target from $261.00 to $241.00 while other firms have maintained or slightly increased their target prices, indicating a consensus rating of "Hold."

Camelot Portfolios LLC acquired a new stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 3,754 shares of the medical instruments supplier's stock, valued at approximately $647,000.

Several other hedge funds also recently bought and sold shares of BDX. Northcape Wealth Management LLC lifted its stake in shares of Becton, Dickinson and Company by 0.5% in the 1st quarter. Northcape Wealth Management LLC now owns 9,814 shares of the medical instruments supplier's stock worth $2,248,000 after acquiring an additional 51 shares during the period. Alpha Omega Wealth Management LLC boosted its holdings in Becton, Dickinson and Company by 5.7% during the first quarter. Alpha Omega Wealth Management LLC now owns 984 shares of the medical instruments supplier's stock worth $225,000 after buying an additional 53 shares in the last quarter. Brady Family Wealth LLC boosted its holdings in Becton, Dickinson and Company by 1.2% during the first quarter. Brady Family Wealth LLC now owns 4,317 shares of the medical instruments supplier's stock worth $989,000 after buying an additional 53 shares in the last quarter. Diversified Trust Co boosted its holdings in Becton, Dickinson and Company by 4.7% during the first quarter. Diversified Trust Co now owns 1,188 shares of the medical instruments supplier's stock worth $272,000 after buying an additional 53 shares in the last quarter. Finally, Horizon Bancorp Inc. IN boosted its holdings in Becton, Dickinson and Company by 10.9% during the first quarter. Horizon Bancorp Inc. IN now owns 569 shares of the medical instruments supplier's stock worth $130,000 after buying an additional 56 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company's stock.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,185 shares of the firm's stock in a transaction dated Friday, July 18th. The shares were sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the transaction, the executive vice president directly owned 4,887 shares of the company's stock, valued at approximately $881,077.23. This trade represents a 19.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Claire Fraser sold 917 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the transaction, the director directly owned 22,226 shares of the company's stock, valued at $4,167,375. This represents a 3.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 2,965 shares of company stock valued at $551,536 over the last ninety days. 0.36% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

BDX has been the subject of several research analyst reports. Barclays reduced their price target on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating for the company in a research report on Tuesday, June 3rd. Piper Sandler reiterated a "neutral" rating and issued a $200.00 target price (up previously from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Morgan Stanley increased their target price on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an "overweight" rating in a research report on Monday, August 11th. Wall Street Zen upgraded shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Finally, Wells Fargo & Company increased their price target on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an "equal weight" rating in a research note on Friday, August 8th. Four research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat.com, Becton, Dickinson and Company has a consensus rating of "Hold" and an average price target of $213.09.

Becton, Dickinson and Company Stock Performance

NYSE:BDX opened at $184.59 on Friday. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99. The firm's fifty day simple moving average is $188.27 and its 200 day simple moving average is $188.72. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. The firm has a market capitalization of $52.91 billion, a PE ratio of 33.20, a PEG ratio of 1.49 and a beta of 0.27.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.40 by $0.28. The company had revenue of $5.51 billion for the quarter, compared to analyst estimates of $5.50 billion. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The business's quarterly revenue was up 10.4% on a year-over-year basis. During the same period last year, the business posted $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, sell-side analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th will be issued a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend is Monday, September 8th. Becton, Dickinson and Company's dividend payout ratio (DPR) is presently 74.82%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.